Group 1 - Yinglian Co., Ltd. expects a net profit increase of 1531.13% to 1672.97% year-on-year for the first three quarters of 2025, with projected revenue of 1.63 billion to 1.65 billion yuan, a growth of 9.49% to 10.83% [1] - Meixin Sheng plans to reduce its shareholding by no more than 1% through centralized bidding and block trading [1] - Huayin Technology signed two sales contracts totaling 402 million yuan, with one contract for special functional materials and another for research project materials [3] Group 2 - Shen Highways reported a total toll revenue of 114 million yuan for August [5] - Dash Smart signed a contract worth 113 million yuan for a smart hospital project [7] - Tianbang Food received an administrative regulatory measure decision from the China Securities Regulatory Commission for failing to disclose information in a timely manner [8] Group 3 - Fashilong plans to invest 250 million yuan to establish a wholly-owned subsidiary focused on AI applications and cloud computing [10] - Junpu Intelligent received a government subsidy of 20 million yuan, accounting for 243.97% of its audited net profit for 2024 [11] - Longyun Co. plans to apply for a bank credit limit of 32 million yuan [12] Group 4 - Yifan Pharmaceutical's subsidiary received acceptance for a drug registration application for a medication used to lower phenylalanine levels in patients [12] - Rundu Co. received a drug registration certificate for a hypertension medication [13] - Huahai Qingke elected a new employee director and appointed a new vice president [17] Group 5 - Wanyi Technology received a government subsidy of 173,000 yuan [19] - Haizheng Pharmaceutical's tacrolimus capsules passed the consistency evaluation for generic drugs [20] - Pulaike's new veterinary vaccine received registration certification [22] Group 6 - Boguang New Materials signed a major sales contract estimated at 4.3 billion to 5 billion yuan for nickel powder products [41] - Electric Soul Network announced plans for shareholders to reduce their holdings by up to 1.63% [42] - Jin Haitong's shareholders plan to reduce their holdings by up to 3% [44]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）9月29日，康弘药业发布公告称，公司于近日收到国家药 品监督管理局签发的依帕司他片的《药品注册证书》，批准注册。 公告显示，依帕司他是一种可逆性的醛糖还原酶非竞争性抑制剂，对醛糖还原酶具有选择性抑制作用。 临床研究显示，依帕司他能抑制糖尿病性外周神经病变患者红细胞中山梨醇的积累，与对照组比较能改 善患者的自觉症状和神经功能障碍。 ...

格隆汇9月29日｜①康弘药业：近日收到国家药监局签发的依帕司他片的药品注册证书。依帕司他片适 应症为糖尿病性神经病变。 ②鲁西化工：进一步推进资源整合、优化管理架构，公司拟吸收合并全资子公司山东聊城鲁西化工第二 化肥有限公司。 ③铜陵有色：2025年半年度利润分配预案拟每10股派发现金红利0.5元（含税）。 ④海泰科：9月29日是"海泰转债"最后一个转股日。9月29日上午收市后，距离"海泰转债"停止转股并赎 回仅剩半个交易日。如投资者未及时转股，可能面临损失。 ⑤松原安全：距离"松原转债"停止转股仅剩最后半个交易日，即9月29日下午交易时段，9月29日收市 后，未实施转股的"松原转债"将停止转股，剩余可转债将按照100.07元/张的价格被强制赎回。若被强制 赎回，投资者可能面临大额投资损失。 ...

康弘药业（002773）(002773.SZ)公告，公司近日收到国家药品监督管理局签发的依帕司他片的《药品 注册证书》，批准注册。该药物适应症为：糖尿病性神经病变。 ...

智通财经APP讯，康弘药业(002773.SZ)公告，公司近日收到国家药品监督管理局签发的依帕司他片的 《药品注册证书》，批准注册。该药物适应症为：糖尿病性神经病变。 ...

南财智讯9月29日电，康弘药业公告，公司收到国家药品监督管理局签发的依帕司他片《药品注册证 书》。该产品用于治疗糖尿病性神经病变。 ...

格隆汇9月29日丨康弘药业(002773.SZ)公布，公司于近日收到国家药品监督管理局签发的依帕司他片的 《药品注册证书》(证书编号：2025S02992)，批准注册。 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符合药品注册的有关要求， 批准注册，发给药品注册证书。 规格：50mg 适应症：糖尿病性神经病变。 注册分类：化学药品 3 类 批准文号：国药准字 H20255572 依帕司他是一种可逆性的醛糖还原酶非竞争性抑制剂，对醛糖还原酶具有选择性抑制作用。临床研究显 示，依帕司他能抑制糖尿病性外周神经病变患者红细胞中山梨醇的积累，与对照组比较能改善患者的自 觉症状和神经功能障碍。 药品名称：依帕司他片 剂型：片剂 ...